Clinical Trial

The Impact of Time Restricted Eating on Type 2 Diabetes

Study acronym: EaT2DM
Terminated
View on ClinicalTrials.gov →
Why the trial stopped
clinical facility could no longer support study conduct; loss of funding, PI left the institution
Summary
Time-restricted feeding limits caloric intake to active daytime hours with fasting for 14 to 16 hours. It has shown great promise as a novel intervention for stabilizing blood glucose, reducing weight, and improving cardiovascular disease outcomes. However, this approach has not been tested on people with diabetes, a group that would benefit from improved blood glucose and weight loss. The impact of Time-Restricted Eating on Type 2 Diabetes Study (EaT2D Study) is a randomized six-day weight stable crossover feeding study in the Day Patient/Outpatient unit of The Rockefeller Hospital investigating how the time of day that meals are eaten affects weight, blood sugar and blood pressure. The investigators will compare an early time-restricted eating intervention (80% of calories consumed before 2 pm) to a usual feeding pattern (50% of calories consumed after 4 pm) among 10 persons with type 2 diabetes to determine effects on blood sugar and small molecules found in the blood. Studies have shown benefits of eating during active periods (mornings and early afternoon) for metabolic health (blood sugar, body weight) compared to eating during inactive periods (evening and bedtime). Eating earlier in the day may lead to reduced sugar stores, burning fat for energy, and decreased inflammation when compared to eating later in the day. The investigators will compare the effects of eating earlier during the day for six days versus later in the day for six days, on blood sugar, blood pressure, blood ketones, and other measures of metabolic health in diabetic participants. Studies in animals supports these benefits.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-19; most recent amendment 2026-01-15.
Status change: Recruiting → Terminated 2026-01-15
Status change: Not Yet Recruiting → Recruiting 2025-09-28
Trial Details
NCT Number NCT06887543
Lead Sponsor Rockefeller University
Collaborators: NYU Langone Health
Conditions Type 2 Diabetes
Enrollment 2 participants
Start Date 2025-05-29
Primary Completion 2025-08-04 (estimated)
Study Completion 2025-08-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-20